Somewhat Positive Media Coverage Somewhat Unlikely to Affect Rigel Pharmaceuticals (RIGL) Share Price
Press coverage about Rigel Pharmaceuticals (NASDAQ:RIGL) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rigel Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.8988690059051 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Analysts’ Review: Rigel Pharmaceutical (RIGL) and Mitsubishi Ufj Financial Group Inc (MTU) – Post Registrar (postregistrar.com)
- Rigel Pharmaceuticals, Inc. (RIGL) Moves Back And Forth on Volatility Analysis – Investing News Update (investingbizz.com)
- Analysts’ Views: Verso Corporation Cmn (VRS) and Rigel Pharmaceutical (RIGL) – Post Registrar (postregistrar.com)
- Rigel Pharmaceuticals, Inc. (RIGL) Investors Watch List Stock – The Stocks News (press release) (thestocksnews.com)
- Rigel Pharmaceuticals, Inc. (RIGL) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
Rigel Pharmaceuticals (RIGL) traded down $0.14 during trading on Friday, reaching $3.75. The company’s stock had a trading volume of 629,537 shares, compared to its average volume of 1,241,156. The firm has a market capitalization of $591.82, a price-to-earnings ratio of -6.21 and a beta of 1.29. Rigel Pharmaceuticals has a 12 month low of $2.14 and a 12 month high of $4.71.
RIGL has been the topic of a number of recent analyst reports. HC Wainwright set a $7.00 price objective on Rigel Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 11th. BidaskClub lowered Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $6.00 price objective on shares of Rigel Pharmaceuticals in a report on Thursday, December 21st. Cantor Fitzgerald initiated coverage on Rigel Pharmaceuticals in a report on Thursday, December 14th. They set an “overweight” rating and a $6.00 price objective on the stock. Finally, ValuEngine lowered Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $5.71.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Rigel Pharmaceuticals (RIGL) Share Price” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-rigel-pharmaceuticals-rigl-share-price/1960436.html.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.